Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

D. Kiss, T. Machackova, K. Souckova, P. Fabian, I. Krepelkova, M. Svoboda, I. Kiss

. 2021 ; 35 (5) : 2809-2814. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025024

BACKGROUND/AIM: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. PATIENTS AND METHODS: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. RESULTS: Expression levels of candidate miRNA biomarkers (miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival (p=0.024). CONCLUSION: We have successfully confirmed miR-92b-3p to be up-regulated in tumor tissue of mCRC patients with good response to bevacizumab/FOLFOX therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025024
003      
CZ-PrNML
005      
20220113104358.0
007      
ta
008      
211013s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12567 $2 doi
035    __
$a (PubMed)34410972
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kiss, David $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Cardiology and Internal Medicine, University Hospital Brno, Brno, Czech Republic $7 xx0268385
245    13
$a An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer / $c D. Kiss, T. Machackova, K. Souckova, P. Fabian, I. Krepelkova, M. Svoboda, I. Kiss
520    9_
$a BACKGROUND/AIM: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. PATIENTS AND METHODS: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. RESULTS: Expression levels of candidate miRNA biomarkers (miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival (p=0.024). CONCLUSION: We have successfully confirmed miR-92b-3p to be up-regulated in tumor tissue of mCRC patients with good response to bevacizumab/FOLFOX therapy.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bevacizumab $x terapeutické užití $7 D000068258
650    _2
$a biologické markery $7 D015415
650    12
$a kolorektální nádory $x farmakoterapie $x genetika $7 D015179
650    _2
$a fluoruracil $7 D005472
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x genetika $7 D035683
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Machackova, Tana $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Souckova, Kamila $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Fabian, Pavel $u Department of Clinical and Experimental Pahology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Krepelkova, Iveta $u BioVendor Laboratorni Medicína a.s., Brno, Czech Republic
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; kiss@mou.cz $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 35, č. 5 (2021), s. 2809-2814
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34410972 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20220113104355 $b ABA008
999    __
$a ok $b bmc $g 1714189 $s 1145531
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 5 $d 2809-2814 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace